Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion
AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly worth up to $2.25 billion to develop AI-designed enzymes for genetic medicines.
More info
